{"protocolSection": {"identificationModule": {"nctId": "NCT01194479", "orgStudyIdInfo": {"id": "HIC1005006832"}, "secondaryIdInfos": [{"id": "R37-20495", "type": "OTHER_GRANT", "domain": "NIDDK"}], "organization": {"fullName": "Yale University", "class": "OTHER"}, "briefTitle": "Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.", "officialTitle": "The Effect of the Beta 2 Agonist, Formoterol, on Recovery From Hypoglycemia"}, "statusModule": {"statusVerifiedDate": "2016-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-08"}, "primaryCompletionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-09-01", "studyFirstSubmitQcDate": "2010-09-01", "studyFirstPostDateStruct": {"date": "2010-09-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-01-28", "resultsFirstSubmitQcDate": "2016-02-26", "resultsFirstPostDateStruct": {"date": "2016-03-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-02-26", "lastUpdatePostDateStruct": {"date": "2016-03-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Yale University", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). The aim of this study is to determine whether a formoterol inhaler can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.", "detailedDescription": "Note: Below is the original detailed description submitted in 2010. The recruitment for this study was stopped at 7 subjects in each study arm. The study design and outcome measures did not change for this study. See below for further details.\n\nOriginal: 15 subjects with well controlled type 1 diabetes and regular hypoglycemia and 15 healthy volunteers will be recruited for this study.\n\nIf you agree to participate in this study, you will be asked to participate in a screening at Yale New Haven Hospital. Each study subject will undergo two hypoglycemic clamp studies (a procedure where the blood sugar is closely regulated with intravenous insulin and glucose.) In these hypoglycemic clamp studies, the subject will be given an inhaler. On one visit the inhaler will contain formoterol capsules and on the other visit, the subject will be given 'dummy' capsules. Subjects will be required to be admitted to the HRU the night before the study so that glucose levels can be stabilized and hypoglycemia avoided."}, "conditionsModule": {"conditions": ["Type 1 Diabetes"], "keywords": ["type 1 diabetes", "hypoglycemia", "formoterol"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 14, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Type 1 Diabetics", "type": "ACTIVE_COMPARATOR", "description": "The active group were participants with type 1 diabetes.", "interventionNames": ["Drug: Formoterol", "Other: Placebo"]}, {"label": "Healthy Volunteers", "type": "OTHER", "description": "The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.", "interventionNames": ["Drug: Formoterol", "Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Formoterol", "description": "Formoterol inhaler, 12mcg capsules, 4 capsules for one administration", "armGroupLabels": ["Healthy Volunteers", "Type 1 Diabetics"], "otherNames": ["Foradil Aerolizer"]}, {"type": "OTHER", "name": "Placebo", "description": "Participants in both arms received placebo on 1 of the 2 visits.", "armGroupLabels": ["Healthy Volunteers", "Type 1 Diabetics"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Glucagon (pg/mL)", "description": "Glucagon levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages.", "timeFrame": "up to 120 minutes"}, {"measure": "Epinephrine (pg/mL)", "description": "Epinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages", "timeFrame": "up to 120 minutes"}, {"measure": "Norepinephrine (pg/mL)", "description": "Norepinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages", "timeFrame": "up to 120 minutes"}], "secondaryOutcomes": [{"measure": "Blood Glucose Levels (Average)", "description": "Blood glucose levels will be checked every 5 minutes during the 120 minute study session in order to maintain blood glucose levels in the normal and hypoglycemic range. Presented is the average of the collected values.", "timeFrame": "Up to 120 minutes"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk)\n* age 18-50\n* BMI 18-30\n\nExclusion Criteria:\n\n* pregnancy\n* significant diabetes complications\n* liver disease, cirrhosis\n* cardiac disease\n* neurological disorder\n* autonomic neuropathy\n* kidney disease\n* lactose intolerance", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert Sherwin, MD", "affiliation": "Yale School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Yale University School of Medicine", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}]}, "referencesModule": {"references": [{"pmid": "26153273", "type": "RESULT", "citation": "Belfort-DeAguiar RD, Naik S, Hwang J, Szepietowska B, Sherwin RS. Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2015 Sep;38(9):1736-41. doi: 10.2337/dc14-2472. Epub 2015 Jul 7."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Healthy subjects and Type 1 Diabetics were recruited to participate in the study. Subjects in either arm were randomized to receive a placebo or the study drug: Formoterol in either the first or second visit.", "groups": [{"id": "FG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo first, the Formoterol."}, {"id": "FG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol first, then Placebo."}, {"id": "FG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received Placebo first, then Formoterol."}, {"id": "FG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol first, then Placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Cross-over at Second Visit", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Healthy Volunteers", "description": "The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.\n\nFormoterol: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration\n\nPlacebo: Participants in both arms received placebo on 1 of the 2 visits."}, {"id": "BG001", "title": "Type 1 Diabetics", "description": "The active group were participants with type 1 diabetes.\n\nFormoterol: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration\n\nPlacebo: Participants in both arms received placebo on 1 of the 2 visits."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36", "spread": "8"}, {"groupId": "BG001", "value": "31", "spread": "11"}, {"groupId": "BG002", "value": "33.2", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Body Mass Index (BMI, kg/m^2)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23.7", "spread": "2.1"}, {"groupId": "BG001", "value": "25.8", "spread": "2.9"}, {"groupId": "BG002", "value": "24.8", "spread": "2.7"}]}]}]}, {"title": "Weight (kg)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.0", "spread": "12.9"}, {"groupId": "BG001", "value": "70.2", "spread": "10.6"}, {"groupId": "BG002", "value": "70.1", "spread": "11.3"}]}]}]}, {"title": "HbA1c (%)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.3", "spread": "2.6"}, {"groupId": "BG001", "value": "6.8", "spread": "2.6"}, {"groupId": "BG002", "value": "6.1", "spread": "1.0"}]}]}]}, {"title": "HbA1c (mmol/mol)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/mol", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.5", "spread": "2.6"}, {"groupId": "BG001", "value": "51.3", "spread": "8.5"}, {"groupId": "BG002", "value": "43.5", "spread": "10.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Glucagon (pg/mL)", "description": "Glucagon levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages.", "populationDescription": "Results are pooled at the arm level and split by placebo and control regardless of randomization order.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "up to 120 minutes", "groups": [{"id": "OG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo on the first or second visit."}, {"id": "OG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol on the first or second visit."}, {"id": "OG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received placebo on the first or second visit."}, {"id": "OG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol on the first or second visit."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "7"}]}], "classes": [{"title": "Basal", "categories": [{"measurements": [{"groupId": "OG000", "value": "76", "spread": "13"}, {"groupId": "OG001", "value": "74", "spread": "11"}, {"groupId": "OG002", "value": "53", "spread": "8"}, {"groupId": "OG003", "value": "56", "spread": "10"}]}]}, {"title": "Euglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "59", "spread": "11"}, {"groupId": "OG001", "value": "58", "spread": "13"}, {"groupId": "OG002", "value": "55", "spread": "10"}, {"groupId": "OG003", "value": "54", "spread": "9"}]}]}, {"title": "Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "66", "spread": "16"}, {"groupId": "OG001", "value": "73", "spread": "18"}, {"groupId": "OG002", "value": "43", "spread": "8"}, {"groupId": "OG003", "value": "46", "spread": "9"}]}]}]}, {"type": "SECONDARY", "title": "Blood Glucose Levels (Average)", "description": "Blood glucose levels will be checked every 5 minutes during the 120 minute study session in order to maintain blood glucose levels in the normal and hypoglycemic range. Presented is the average of the collected values.", "populationDescription": "Subjects are pooled across randomized conditions in their respective study arms and reported overall.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Up to 120 minutes", "groups": [{"id": "OG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo on the first or second visit."}, {"id": "OG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol on the first or second visit."}, {"id": "OG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received placebo on the first or second visit."}, {"id": "OG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol on the first or second visit."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "7"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.38", "spread": "3.45"}, {"groupId": "OG001", "value": "58.39", "spread": "2.40"}, {"groupId": "OG002", "value": "53.21", "spread": "2.57"}, {"groupId": "OG003", "value": "55.43", "spread": "4.40"}]}]}]}, {"type": "PRIMARY", "title": "Epinephrine (pg/mL)", "description": "Epinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages", "populationDescription": "Results are pooled at the arm level and split by placebo and control regardless of randomization order.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "up to 120 minutes", "groups": [{"id": "OG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo on the first or second visit."}, {"id": "OG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol on the first or second visit."}, {"id": "OG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received placebo on the first or second visit."}, {"id": "OG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol on the first or second visit."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "7"}]}], "classes": [{"title": "Basal", "categories": [{"measurements": [{"groupId": "OG000", "value": "15", "spread": "4"}, {"groupId": "OG001", "value": "16", "spread": "5"}, {"groupId": "OG002", "value": "18", "spread": "4"}, {"groupId": "OG003", "value": "17", "spread": "5"}]}]}, {"title": "Euglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "12", "spread": "3"}, {"groupId": "OG001", "value": "12", "spread": "4"}, {"groupId": "OG002", "value": "21", "spread": "5"}, {"groupId": "OG003", "value": "13", "spread": "2"}]}]}, {"title": "Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "46", "spread": "15"}, {"groupId": "OG001", "value": "55", "spread": "22"}, {"groupId": "OG002", "value": "44", "spread": "15"}, {"groupId": "OG003", "value": "19", "spread": "4"}]}]}]}, {"type": "PRIMARY", "title": "Norepinephrine (pg/mL)", "description": "Norepinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages", "populationDescription": "Results are pooled at the arm level and split by placebo and control regardless of randomization order.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "up to 120 minutes", "groups": [{"id": "OG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo on the first or second visit."}, {"id": "OG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol on the first or second visit."}, {"id": "OG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received placebo on the first or second visit."}, {"id": "OG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol on the first or second visit."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "7"}]}], "classes": [{"title": "Basal", "categories": [{"measurements": [{"groupId": "OG000", "value": "185", "spread": "37"}, {"groupId": "OG001", "value": "192", "spread": "24"}, {"groupId": "OG002", "value": "180", "spread": "28"}, {"groupId": "OG003", "value": "133", "spread": "13"}]}]}, {"title": "Euglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "216", "spread": "31"}, {"groupId": "OG001", "value": "273", "spread": "22"}, {"groupId": "OG002", "value": "226", "spread": "31"}, {"groupId": "OG003", "value": "211", "spread": "30"}]}]}, {"title": "Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "156", "spread": "21"}, {"groupId": "OG001", "value": "181", "spread": "14"}, {"groupId": "OG002", "value": "241", "spread": "30"}, {"groupId": "OG003", "value": "190", "spread": "32"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events are reported by the study arm and randomized visit order.", "eventGroups": [{"id": "EG000", "title": "Control: Placebo", "description": "Healthy volunteers that received Placebo on the first visit.", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 2, "otherNumAtRisk": 7}, {"id": "EG001", "title": "Control: Formoterol", "description": "Healthy volunteers that received Formoterol on the first visit.", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 3, "otherNumAtRisk": 7}, {"id": "EG002", "title": "Type 1 Diabetics: Placebo", "description": "Type 1 Diabetics that received placebo on the first visit.", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 0, "otherNumAtRisk": 7}, {"id": "EG003", "title": "Type 1 Diabetics: Formoterol", "description": "Type 1 Diabetics that received Formoterol on the first visit.", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 2, "otherNumAtRisk": 7}], "otherEvents": [{"term": "Shakiness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 7}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Hunger", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Tiredness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Mild Palpitations", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Light Headedness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Robert Sherwin, MD", "organization": "Department of Internal Medicine and Endocrinology, Yale University School of Medicine, New Haven, CT", "email": "robert.sherwin@yale.edu", "phone": "(203) 785-3482"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}, {"id": "D000007003", "term": "Hypoglycemia"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M10053", "name": "Hypoglycemia", "asFound": "Hypoglycemia", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Type 1 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}